Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Using Single-Cell Sequencing to Uncover Differences in Stem Cell-Derived Cardiomyocytes for a Personalized Molecular Approach to Treating Heart Failure

FY 2023-24

Summary
Heart failure (HF) is an alarming cause of cardiovascular mortality. Approximately 850,000 Canadians are affected by HF despite advances in cardiovascular medicine. HF is a progressive disease that impairs the pumping of the heart caused by cell death. Most cell death comes from cardiomyocytes (CMs); muscle cells that generate contractility in the heart. Recent research has focused on the transplantation of CMs into patients suffering from HF. Unfortunately, this concept remains challenging because every HF patient is different. To personalize treatment, researchers have turned to pluripotent stem cells (PSCs), which are cells that may transform into any type of cell in the human body. Currently, researchers are creating personalized PSCs from individual patients and turning them into CMs. However, the molecular differences of CMs created from patients of different sex, gender, ethnicity, or even socioeconomic status are not well characterized. Our objective is to understand the molecular basis of HF and investigate molecular differences of CMs produced from PSCs belonging to different patient demographics. We also intend to improve patient-generated CMs by increasing their functionality. By completing our objectives, we may uncover molecular differences in HF and patient PSC-CMs in various demographics. Furthermore, improving CM functionality may increase its contractile properties. We intend to use the results of this study to create more clinically translatable patient PSC-CMs. We also have available 289 unique healthy and patient samples which we may use to broaden the scope of our project. Our research may one day uncover new treatments for HF patients belonging to all demographics.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
525808
Name
Lung Bryan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Using Single-Cell Sequencing to Uncover Differences in Stem Cell-Derived Cardiomyocytes for a Personalized Molecular Approach to Treating Heart Failure
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cardiomyocytes; Computational Biology; Dilated Cardiomyopathy; Heart Failure; Induced Pluripotent Stem Cells; Molecular Pathway Analysis; Patient-Specific Differences; Personalized Medicine; Sequencing; Single-Cell Rna Transcriptomics
Abstract
Heart failure (HF) is an alarming cause of cardiovascular mortality. Approximately 850,000 Canadians are affected by HF despite advances in cardiovascular medicine. HF is a progressive disease that impairs the pumping of the heart caused by cell death. Most cell death comes from cardiomyocytes (CMs); muscle cells that generate contractility in the heart. Recent research has focused on the transplantation of CMs into patients suffering from HF. Unfortunately, this concept remains challenging because every HF patient is different. To personalize treatment, researchers have turned to pluripotent stem cells (PSCs), which are cells that may transform into any type of cell in the human body. Currently, researchers are creating personalized PSCs from individual patients and turning them into CMs. However, the molecular differences of CMs created from patients of different sex, gender, ethnicity, or even socioeconomic status are not well characterized. Our objective is to understand the molecular basis of HF and investigate molecular differences of CMs produced from PSCs belonging to different patient demographics. We also intend to improve patient-generated CMs by increasing their functionality. By completing our objectives, we may uncover molecular differences in HF and patient PSC-CMs in various demographics. Furthermore, improving CM functionality may increase its contractile properties. We intend to use the results of this study to create more clinically translatable patient PSC-CMs. We also have available 289 unique healthy and patient samples which we may use to broaden the scope of our project. Our research may one day uncover new treatments for HF patients belonging to all demographics.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lung, Bryan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~